Logo image of UTRS

MINERVA SURGICAL INC (UTRS) Stock Fundamental Analysis

USA - NASDAQ:UTRS - US60343F2056 - Common Stock

1.48 USD
-0.07 (-4.52%)
Last: 12/28/2023, 8:06:43 PM
1.53 USD
+0.05 (+3.38%)
After Hours: 12/28/2023, 8:06:43 PM
Fundamental Rating

2

Taking everything into account, UTRS scores 2 out of 10 in our fundamental rating. UTRS was compared to 191 industry peers in the Health Care Equipment & Supplies industry. UTRS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, UTRS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year UTRS has reported negative net income.
UTRS had a negative operating cash flow in the past year.
UTRS Yearly Net Income VS EBIT VS OCF VS FCFUTRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -45.95%, UTRS is not doing good in the industry: 66.17% of the companies in the same industry are doing better.
The Return On Equity of UTRS (-164.78%) is worse than 77.11% of its industry peers.
Industry RankSector Rank
ROA -45.95%
ROE -164.78%
ROIC N/A
ROA(3y)-29.33%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UTRS Yearly ROA, ROE, ROICUTRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 50 -50 -100 -150

1.3 Margins

UTRS has a Gross Margin of 54.19%. This is comparable to the rest of the industry: UTRS outperforms 50.75% of its industry peers.
UTRS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for UTRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.06%
GM growth 5YN/A
UTRS Yearly Profit, Operating, Gross MarginsUTRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 50 -50 -100 -150 -200

More info and screens

1

2. Health

2.1 Basic Checks

UTRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
UTRS has more shares outstanding than it did 1 year ago.
UTRS has a worse debt/assets ratio than last year.
UTRS Yearly Shares OutstandingUTRS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 500K 1M
UTRS Yearly Total Debt VS Total AssetsUTRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

UTRS has an Altman-Z score of -6.13. This is a bad value and indicates that UTRS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -6.13, UTRS is not doing good in the industry: 70.65% of the companies in the same industry are doing better.
A Debt/Equity ratio of 1.37 is on the high side and indicates that UTRS has dependencies on debt financing.
With a Debt to Equity ratio value of 1.37, UTRS is not doing good in the industry: 82.59% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF N/A
Altman-Z -6.13
ROIC/WACCN/A
WACC8.14%
UTRS Yearly LT Debt VS Equity VS FCFUTRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

UTRS has a Current Ratio of 1.88. This is a normal value and indicates that UTRS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.88, UTRS is doing worse than 75.62% of the companies in the same industry.
A Quick Ratio of 1.02 indicates that UTRS should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.02, UTRS is doing worse than 81.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.02
UTRS Yearly Current Assets VS Current LiabilitesUTRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

UTRS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.66%, which is quite impressive.
Looking at the last year, UTRS shows a small growth in Revenue. The Revenue has grown by 3.07% in the last year.
UTRS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.58% yearly.
EPS 1Y (TTM)58.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.88%
Revenue 1Y (TTM)3.07%
Revenue growth 3Y24.58%
Revenue growth 5YN/A
Sales Q2Q%-4.92%

3.2 Future

The Earnings Per Share is expected to grow by 23.40% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 10.85% on average over the next years. This is quite good.
EPS Next Y82.41%
EPS Next 2Y36.93%
EPS Next 3Y23.4%
EPS Next 5YN/A
Revenue Next Year2.99%
Revenue Next 2Y8.86%
Revenue Next 3Y10.85%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
UTRS Yearly Revenue VS EstimatesUTRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
UTRS Yearly EPS VS EstimatesUTRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

UTRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year UTRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UTRS Price Earnings VS Forward Price EarningsUTRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UTRS Per share dataUTRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as UTRS's earnings are expected to grow with 23.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.93%
EPS Next 3Y23.4%

More info and screens

0

5. Dividend

5.1 Amount

UTRS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MINERVA SURGICAL INC

NASDAQ:UTRS (12/28/2023, 8:06:43 PM)

After market: 1.53 +0.05 (+3.38%)

1.48

-0.07 (-4.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13 2023-11-13/amc
Earnings (Next)03-19 2024-03-19/amc
Inst Owners0.31%
Inst Owner Change0%
Ins Owners1799.28%
Ins Owner Change0%
Market Cap13.14M
Analysts82.86
Price Target3.06 (106.76%)
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.06%
Min EPS beat(2)20.59%
Max EPS beat(2)45.53%
EPS beat(4)3
Avg EPS beat(4)16.45%
Min EPS beat(4)-6.95%
Max EPS beat(4)45.53%
EPS beat(8)5
Avg EPS beat(8)7.58%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-8.42%
Min Revenue beat(2)-11.14%
Max Revenue beat(2)-5.7%
Revenue beat(4)1
Avg Revenue beat(4)-3.51%
Min Revenue beat(4)-11.14%
Max Revenue beat(4)4.81%
Revenue beat(8)1
Avg Revenue beat(8)-2.78%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1250%
EPS NY rev (1m)0%
EPS NY rev (3m)-1750%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.25
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.21
EYN/A
EPS(NY)-2.95
Fwd EYN/A
FCF(TTM)-4.37
FCFYN/A
OCF(TTM)-4.36
OCFYN/A
SpS5.82
BVpS2.29
TBVpS-0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.95%
ROE -164.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.19%
FCFM N/A
ROA(3y)-29.33%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.06%
GM growth 5YN/A
F-Score2
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.57%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.88
Quick Ratio 1.02
Altman-Z -6.13
F-Score2
WACC8.14%
ROIC/WACCN/A
Cap/Depr(3y)4.15%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.81%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.88%
EPS Next Y82.41%
EPS Next 2Y36.93%
EPS Next 3Y23.4%
EPS Next 5YN/A
Revenue 1Y (TTM)3.07%
Revenue growth 3Y24.58%
Revenue growth 5YN/A
Sales Q2Q%-4.92%
Revenue Next Year2.99%
Revenue Next 2Y8.86%
Revenue Next 3Y10.85%
Revenue Next 5YN/A
EBIT growth 1Y9.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.05%
EBIT Next 3Y11.17%
EBIT Next 5YN/A
FCF growth 1Y-185.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-198.46%
OCF growth 3YN/A
OCF growth 5YN/A